(Q33577145)

28 July 2017

title

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. (English)

1 reference

extensively drug-resistant tuberculosis

28 July 2017

0 references

United States of America

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

5

Lori Armstrong

1 reference

28 July 2017

Suzanne M Marks

1

1 reference

28 July 2017

Jennifer Flood

2

1 reference

28 July 2017

Barbara Seaworth

3

1 reference

28 July 2017

Yael Hirsch-Moverman

4

1 reference

28 July 2017

Sundari Mase

6

1 reference

28 July 2017

Katya Salcedo

7

1 reference

28 July 2017

Peter Oh

8

1 reference

28 July 2017

Edward A Graviss

9

1 reference

28 July 2017

Paul W Colson

10

1 reference

28 July 2017

Lisa Armitige

11

1 reference

28 July 2017

Manuel Revuelta

12

1 reference

28 July 2017

Kathryn Sheeran

13

1 reference

28 July 2017

TB Epidemiologic Studies Consortium

14

1 reference

28 July 2017

publication date

1 May 2014

1 reference

Emerging Infectious Diseases

28 July 2017

published in

1 reference

28 July 2017

volume

20

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

812-821

1 reference

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

The costs of treating breast cancer in the US: a synthesis of published evidence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Extensively drug-resistant tuberculosis in california, 1993-2006.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Public-private collaboration for multidrug-resistant tuberculosis control in New York City.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Costs of patients hospitalized for multidrug-resistant tuberculosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Tuberculosis in New York City--turning the tide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Return on public health investment: CDC's Expanded HIV Testing Initiative

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Extensively drug-resistant tuberculosis in the United States, 1993-2007.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012799

31 October 2018

Identifiers

DOI

10.3201/EID2005.131037

1 reference

28 July 2017

1 reference

28 July 2017

1 reference